vs
辉瑞（PFE）与优步（UBER）财务数据对比。点击上方公司名可切换其他公司
辉瑞的季度营收约是优步的1.2倍（$17.6B vs $14.4B），优步净利率更高（2.1% vs -9.4%，领先11.4%），优步同比增速更快（20.1% vs -1.2%），辉瑞自由现金流更多（$4.5B vs $2.8B），过去两年优步的营收复合增速更高（19.1% vs 8.6%）
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
优步是总部位于美国加利福尼亚州旧金山的跨国出行科技企业，核心业务涵盖网约车、快递、食品配送及货运服务，业务覆盖全球约70个国家和15000座城市，是全球规模最大的共享出行平台，月活用户超1.8亿，活跃司机及配送员超600万。
PFE vs UBER — 直观对比
营收规模更大
PFE
是对方的1.2倍
$14.4B
营收增速更快
UBER
高出21.3%
-1.2%
净利率更高
UBER
高出11.4%
-9.4%
自由现金流更多
PFE
多$1.7B
$2.8B
两年增速更快
UBER
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.6B | $14.4B |
| 净利润 | $-1.6B | $296.0M |
| 毛利率 | 70.0% | — |
| 营业利润率 | -9.4% | 12.3% |
| 净利率 | -9.4% | 2.1% |
| 营收同比 | -1.2% | 20.1% |
| 净利润同比 | -501.7% | -95.7% |
| 每股收益（稀释后） | $-0.29 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFEUBER
| Q4 25 | $17.6B | $14.4B | ||
| Q3 25 | $16.7B | $13.5B | ||
| Q2 25 | $14.7B | $12.7B | ||
| Q1 25 | $13.7B | $11.5B | ||
| Q4 24 | $17.8B | $12.0B | ||
| Q3 24 | $17.7B | $11.2B | ||
| Q2 24 | $13.3B | $10.7B | ||
| Q1 24 | $14.9B | $10.1B |
净利润PFEUBER
| Q4 25 | $-1.6B | $296.0M | ||
| Q3 25 | $3.5B | $6.6B | ||
| Q2 25 | $2.9B | $1.4B | ||
| Q1 25 | $3.0B | $1.8B | ||
| Q4 24 | $410.0M | $6.9B | ||
| Q3 24 | $4.5B | $2.6B | ||
| Q2 24 | $41.0M | $1.0B | ||
| Q1 24 | $3.1B | $-654.0M |
毛利率PFEUBER
| Q4 25 | 70.0% | — | ||
| Q3 25 | 74.9% | — | ||
| Q2 25 | 74.2% | — | ||
| Q1 25 | 79.3% | — | ||
| Q4 24 | 66.7% | — | ||
| Q3 24 | 70.3% | — | ||
| Q2 24 | 75.2% | — | ||
| Q1 24 | 77.3% | — |
营业利润率PFEUBER
| Q4 25 | -9.4% | 12.3% | ||
| Q3 25 | 20.0% | 8.3% | ||
| Q2 25 | 20.8% | 11.5% | ||
| Q1 25 | 20.3% | 10.6% | ||
| Q4 24 | -0.1% | 6.4% | ||
| Q3 24 | 26.6% | 9.5% | ||
| Q2 24 | -0.8% | 7.4% | ||
| Q1 24 | 23.0% | 1.7% |
净利率PFEUBER
| Q4 25 | -9.4% | 2.1% | ||
| Q3 25 | 21.3% | 49.2% | ||
| Q2 25 | 19.9% | 10.7% | ||
| Q1 25 | 21.6% | 15.4% | ||
| Q4 24 | 2.3% | 57.6% | ||
| Q3 24 | 25.2% | 23.3% | ||
| Q2 24 | 0.3% | 9.5% | ||
| Q1 24 | 20.9% | -6.5% |
每股收益（稀释后）PFEUBER
| Q4 25 | $-0.29 | $0.16 | ||
| Q3 25 | $0.62 | $3.11 | ||
| Q2 25 | $0.51 | $0.63 | ||
| Q1 25 | $0.52 | $0.83 | ||
| Q4 24 | $0.07 | $3.21 | ||
| Q3 24 | $0.78 | $1.20 | ||
| Q2 24 | $0.01 | $0.47 | ||
| Q1 24 | $0.55 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $7.6B |
| 总债务越低越好 | — | $10.6B |
| 股东权益账面价值 | $86.5B | $27.0B |
| 总资产 | $208.2B | $61.8B |
| 负债/权益比越低杠杆越低 | — | 0.39× |
8季度趋势，按日历期对齐
现金及短期投资PFEUBER
| Q4 25 | $1.1B | $7.6B | ||
| Q3 25 | $1.3B | $9.1B | ||
| Q2 25 | $1.6B | $7.4B | ||
| Q1 25 | $1.4B | $6.0B | ||
| Q4 24 | $1.0B | $7.0B | ||
| Q3 24 | $1.1B | $9.1B | ||
| Q2 24 | $1.1B | $6.3B | ||
| Q1 24 | $719.0M | $5.8B |
总债务PFEUBER
| Q4 25 | — | $10.6B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $9.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PFEUBER
| Q4 25 | $86.5B | $27.0B | ||
| Q3 25 | $92.8B | $28.1B | ||
| Q2 25 | $88.7B | $22.6B | ||
| Q1 25 | $90.3B | $22.0B | ||
| Q4 24 | $88.2B | $21.6B | ||
| Q3 24 | $92.3B | $14.8B | ||
| Q2 24 | $87.7B | $12.3B | ||
| Q1 24 | $92.3B | $11.1B |
总资产PFEUBER
| Q4 25 | $208.2B | $61.8B | ||
| Q3 25 | $208.7B | $63.3B | ||
| Q2 25 | $206.1B | $56.0B | ||
| Q1 25 | $208.0B | $52.8B | ||
| Q4 24 | $213.4B | $51.2B | ||
| Q3 24 | $219.5B | $47.1B | ||
| Q2 24 | $216.2B | $41.5B | ||
| Q1 24 | $221.1B | $39.6B |
负债/权益比PFEUBER
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.3B | $2.9B |
| 自由现金流经营现金流 - 资本支出 | $4.5B | $2.8B |
| 自由现金流率自由现金流/营收 | 25.6% | 19.5% |
| 资本支出强度资本支出/营收 | 4.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 9.74× |
| 过去12个月自由现金流最近4个季度 | $9.1B | $9.8B |
8季度趋势，按日历期对齐
经营现金流PFEUBER
| Q4 25 | $5.3B | $2.9B | ||
| Q3 25 | $4.6B | $2.3B | ||
| Q2 25 | $-582.0M | $2.6B | ||
| Q1 25 | $2.3B | $2.3B | ||
| Q4 24 | $6.7B | $1.8B | ||
| Q3 24 | $6.7B | $2.2B | ||
| Q2 24 | $-1.8B | $1.8B | ||
| Q1 24 | $1.1B | $1.4B |
自由现金流PFEUBER
| Q4 25 | $4.5B | $2.8B | ||
| Q3 25 | $4.0B | $2.2B | ||
| Q2 25 | $-1.2B | $2.5B | ||
| Q1 25 | $1.8B | $2.3B | ||
| Q4 24 | $5.8B | $1.7B | ||
| Q3 24 | $6.1B | $2.1B | ||
| Q2 24 | $-2.4B | $1.7B | ||
| Q1 24 | $386.0M | $1.4B |
自由现金流率PFEUBER
| Q4 25 | 25.6% | 19.5% | ||
| Q3 25 | 24.0% | 16.6% | ||
| Q2 25 | -8.2% | 19.6% | ||
| Q1 25 | 12.9% | 19.5% | ||
| Q4 24 | 32.7% | 14.3% | ||
| Q3 24 | 34.3% | 18.9% | ||
| Q2 24 | -18.2% | 16.1% | ||
| Q1 24 | 2.6% | 13.4% |
资本支出强度PFEUBER
| Q4 25 | 4.8% | 0.5% | ||
| Q3 25 | 3.6% | 0.7% | ||
| Q2 25 | 4.2% | 0.7% | ||
| Q1 25 | 4.1% | 0.6% | ||
| Q4 24 | 5.2% | 0.4% | ||
| Q3 24 | 3.7% | 0.4% | ||
| Q2 24 | 4.8% | 0.9% | ||
| Q1 24 | 4.7% | 0.6% |
现金转化率PFEUBER
| Q4 25 | — | 9.74× | ||
| Q3 25 | 1.30× | 0.35× | ||
| Q2 25 | -0.20× | 1.89× | ||
| Q1 25 | 0.79× | 1.31× | ||
| Q4 24 | 16.39× | 0.25× | ||
| Q3 24 | 1.50× | 0.82× | ||
| Q2 24 | -43.44× | 1.79× | ||
| Q1 24 | 0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
UBER
| Mobility | $8.2B | 57% |
| Delivery | $4.9B | 34% |
| Freight | $1.3B | 9% |
